日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Author Correction: DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B

作者更正:DKN-01 和替雷利珠单抗作为 DKK1 高表达胃食管腺癌二线治疗:DisTinGuish 试验 B 部分

Lee, Keun-Wook; Mahalingam, Devalingam; Shim, Byoung Yong; Kim, In-Ho; Oh, Do-Youn; Uronis, Hope; Sym, Sun Jin; Sonbol, Mohamad; Almhanna, Khaldoun; Tejani, Mohamedtaki A; Kang, Beodeul; Kagey, Michael H; Stilian, Melissa; Jia, Calvin; Sirard, Cynthia A; Altura, Rachel; Ajani, Jaffer A; Klempner, Samuel J

DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish

DKN-01联合替雷利珠单抗和化疗作为晚期胃癌或胃食管交界处腺癌的一线治疗:DisTinGuish

Klempner, Samuel J; Sonbol, Mohamad Bassam; Wainberg, Zev A; Uronis, Hope Elizabeth; Chiu, Vi K; Scott, Aaron James; Iqbal, Syma; Tejani, Mohamedtaki Abdulaziz; Chung, Vincent; Stilian, Melissa C; Thoma, Mathis; Zhang, Ying; Kagey, Michael H; Baum, Jason; Sirard, Cynthia A; Altura, Rachel A; Ajani, Jaffer A

DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B

DKN-01 和替雷利珠单抗作为 DKK1 高表达胃食管腺癌的二线治疗:DisTinGuish 试验 B 部分

Lee, Keun-Wook; Mahalingam, Devalingam; Shim, Byoung Yong; Kim, In-Ho; Oh, Do-Youn; Uronis, Hope; Sym, Sun Jin; Sonbol, Mohamad; Almhanna, Khaldoun; Tejani, Mohamedtaki A; Kang, Beodeul; Kagey, Michael H; Stilian, Melissa; Jia, Calvin; Sirard, Cynthia A; Altura, Rachel; Ajani, Jaffer A; Klempner, Samuel J

First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors

首个抗免疫球蛋白样转录物4髓系特异性抗体MK-4830可消除晚期实体瘤患者的PD-1耐药机制

Siu, Lillian L; Wang, Ding; Hilton, John; Geva, Ravit; Rasco, Drew; Perets, Ruth; Abraham, Anson K; Wilson, Douglas C; Markensohn, Julia F; Lunceford, Jared; Suttner, Leah; Siddiqi, Shabana; Altura, Rachel A; Maurice-Dror, Corinne

Correction: First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors

更正:首创的抗免疫球蛋白样转录物4髓系特异性抗体MK-4830可消除晚期实体瘤患者的PD-1耐药机制

Siu, Lillian L; Wang, Ding; Hilton, John; Geva, Ravit; Rasco, Drew; Perets, Ruth; Abraham, Anson K; Wilson, Douglas C; Markensohn, Julia F; Lunceford, Jared; Suttner, Leah; Siddiqi, Shabana; Altura, Rachel A; Maurice-Dror, Corinne

Identification of predictive genetic signatures of Cytarabine responsiveness using a 3D acute myeloid leukaemia model.

利用 3D 急性髓系白血病模型鉴定阿糖胞苷反应性的预测性遗传特征

Xu Haiyan, Muise Eric S, Javaid Sarah, Chen Lan, Cristescu Razvan, Mansueto My Sam, Follmer Nicole, Cho Jennifer, Kerr Kimberley, Altura Rachel, Machacek Michelle, Nicholson Benjamin, Addona George, Kariv Ilona, Chen Hongmin

Histone deacetylase 6 (HDAC6) deacetylates survivin for its nuclear export in breast cancer.

组蛋白去乙酰化酶 6 (HDAC6) 使乳腺癌细胞中的 survivin 去乙酰化,从而促进其核输出

Riolo Matthew T, Cooper Zachary A, Holloway Michael P, Cheng Yan, Bianchi Cesario, Yakirevich Evgeny, Ma Li, Chin Y Eugene, Altura Rachel A

Up-regulation of survivin by the E2A-HLF chimera is indispensable for the survival of t(17;19)-positive leukemia cells.

E2A-HLF嵌合体上调survivin对于t(17;19)阳性白血病细胞的存活是必不可少的

Okuya Mayuko, Kurosawa Hidemitsu, Kikuchi Jiro, Furukawa Yusuke, Matsui Hirotaka, Aki Daisuke, Matsunaga Takayuki, Inukai Takeshi, Goto Hiroaki, Altura Rachel A, Sugita Kenich, Arisaka Osamu, Look A Thomas, Inaba Toshiya

Postnatal expansion of the pancreatic beta-cell mass is dependent on survivin

胰岛β细胞数量的出生后扩增依赖于存活素。

Jiang, Yuying; Nishimura, Wataru; Devor-Henneman, Deborah; Kusewitt, Donna; Wang, Haijuan; Holloway, Michael P; Dohi, Takehiko; Sabo, Edmond; Robinson, Michael L; Altieri, Dario C; Sharma, Arun; Altura, Rachel A